Claims

~~[Claim 1]~~

~~An agent for improving early insulin secretory capacity, comprising, as an active ingredient, a composition comprising 1×10^{10} or more viable cells of a lactic acid bacterium.~~

~~[Claim 2]~~

~~The agent for improving early insulin secretory capacity according to claim 1, wherein the agent for improving early insulin secretory capacity is configured such that 1×10^{10} or more viable cells of a lactic acid bacterium are ingested per day.~~

~~[Claim 3]~~

~~The agent for improving early insulin secretory capacity according to claim 1 or 2, wherein the lactic acid bacterium is a lactic acid bacterium belonging to the genus Lactobacillus.~~

~~[Claim 4]~~

~~The agent for improving early insulin secretory capacity according to any one of claims 1 to 3, wherein the lactic acid bacterium is Lactobacillus casei.~~

~~[Claim 5]~~

~~The agent for improving early insulin secretory capacity according to any one of claims 1 to 4, wherein the lactic acid bacterium is Lactobacillus casei YIT9029.~~

[Claim ~~6~~1]

Use of a composition comprising 1×10^{10} or more viable cells of a lactic acid bacterium for producing an agent for improving early insulin secretory capacity.

~~[Claim 7]~~

~~A composition comprising 1×10^{10} or more viable cells of a lactic acid bacterium for use in improving early insulin secretory capacity.~~

~~[Claim 8]~~

~~A method for improving early insulin secretory capacity, comprising administering to a subject in need thereof or ingesting an effective amount of a composition comprising 1×10^{10} or more viable cells of a lactic acid bacterium.~~

~~[Claim 9]~~

~~The method for improving early insulin secretory capacity according to claim 8, wherein 1×10^{10} or more viable cells of a lactic acid bacterium are ingested per day.~~

[Claim 2]

The use according to claim 1, wherein the agent for improving early insulin secretory capacity is configured such that 1×10^{10} or more viable cells of a lactic acid bacterium are ingested per day.

[Claim 3]

The use according to claim 1 or 2, wherein the agent for improving early insulin secretory capacity is to be administered to a human subject having an early insulinogenic index of less than 0.4.

[Claim 4]

The use according to any one of claims 1 to 3, wherein the lactic acid bacterium is a lactic acid bacterium belonging to the genus Lactobacillus.

[Claim 5]

The use according to any one of claims 1 to 4, wherein the lactic acid bacterium is Lactobacillus casei.

[Claim 6]

The use according to any one of claims 1 to 5, wherein the lactic acid bacterium is Lactobacillus casei YIT9029.